Energenesis Biomedical CO.,LTD. (TPE:6657)

Taiwan · Delayed Price · Currency is TWD

35.30

-0.80 (-2.22%)

At close: Jul 9, 2026

-41.26% (1Y)

Market Cap	3.10B -49.0%
Revenue (ttm)	7.85M +3.9%
Net Income	-207.74M
EPS	-2.35
Shares Out	87.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	94,588
Open	36.10
Previous Close	36.10
Day's Range	35.30 - 36.10
52-Week Range	31.50 - 64.80
Beta	0.43
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About TPE:6657

Energenesis Biomedical CO.,LTD. operates in the biomedicine industry in Taiwan. It provides ENERGI-F703, which is Phase III clinical trial for use in treatment of diabetic foot ulcers; ENERGI-F701, a topical tonic for the treatment of alopecia that is in Phase II clinical trial; ENERGI-F711, a burn cream; ENERGI-F703VLU, a gel that treats venous leg ulcers; ENERGI-F703EB, a topical cream for treating wounds in hereditary epidermolysis bullosa; ENERGI-F702 to treat metabolic diseases; ENERGI-F704 for the treatment of inflammatory bowel disease; ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 35

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 6657

Full Company Profile

Financial Performance

In 2025, TPE:6657's revenue was 7.67 million, a decrease of -0.97% compared to the previous year's 7.75 million. Losses were -258.40 million, 11.8% more than in 2024.

Financial Statements